10-country partnership in Africa and Southeast Asia—to introduce COVID oral antivirals and national test-and-treat programs—announced by new public-private consortium

As Omicron subvariants continue to emerge and spread, the COVID Treatment Quick Start Consortium will ensure treatments reach patients in low- and middle-income countries at urgent pace

DURHAM, N.C., SEPTEMBER 7, 2022—As the latest subvariant of COVID-19 continues to spread, a new test-and-treat consortium announced today that it is moving quickly to support Ministries of Health in 10 low- and middle-income countries to provide oral antiviral treatments immediately to high-risk patients and scale up wider access through 2023.

The COVID Treatment Quick Start Consortium brings together Duke University, the Clinton Health Access Initiative (CHAI), COVID Collaborative, and Americares as implementing partners, with support from the Open Society Foundations, Pfizer and the Conrad N. Hilton Foundation. The consortium will support governments to introduce and scale up access to new and effective COVID-19 oral antiviral therapies in high-risk populations and expects patients to start receiving treatment in select countries in September. Partner countries include Ghana, Kenya, Laos, Malawi, Nigeria, Rwanda, South Africa, Uganda, Zambia, and Zimbabwe.

"We are eager to continue the fight against the COVID-19 pandemic and make sure it does not become entrenched in our society," said Prof Claude Muvunyi, Director General, Rwanda Biomedical Center. "The Quick Start Consortium will help us to continue to build and strengthen a resilient healthcare system, quickly find the patients who need treatment, and make sure they get needed medicines—regardless of socio-economic status. Like so many other diseases, COVID-19 won't go away if you just ignore it."

The project will kick-start programs through a donation by Pfizer of 100,000 courses of PAXLOVID™ (nirmatrelvir/ritonavir), for which the World Health Organization (WHO) issued a strong recommendation for use in high-risk individuals with mild to moderate COVID-19, administered within five days of symptom onset. These test-and-treat programs will shift to using quality assured, low-cost
generics when they become available to facilitate wider adoption throughout low- and middle-income countries.

“Having oral antivirals for COVID is something we have always looked forward to, and we are thus excited to be part of an initiative accelerating PAXLOVID™ for use for COVID management,” said Professor Lloyd B. Mulenga, Director of Infectious Diseases for the Ministry of Health, Zambia. “With this new milestone, we expect less admissions and also fewer COVID related deaths leading to a reduced burden on our health system.”

In addition to donating PAXLOVID™, Pfizer will provide financial support to help further the activities and objectives of the consortium but will not participate in project design or have access to country-level data generated through operational research.

“We have seen throughout the global COVID-19 response that new life-saving interventions like vaccines and treatments are not quickly reaching those most in need around the world,” said Dr. Krishna Udayakumar, Founding Director of the Duke Global Health Innovation Center. “The Quick Start Consortium is partnering with governments to bring urgently needed medicines to high-risk populations in countries that do not have easy access to such innovations.”

This effort to close gaps in access to new COVID-19 medicines comes as the subvariant Omicron BA.5 has become a primary source of COVID-19 infections this summer, according to the WHO. The virus has remained a Public Health Emergency of International Concern since January 20, 2020.

“The program will provide governments with catalytic access to the drugs and technical assistance needed to quickly scale up testing and treatment to reach those who need it most. CHAI and our Quick Start partners are deeply committed to correcting the injustice of essential, lifesaving COVID-19 tools disproportionately available to those lucky enough to live in high-income markets,” said Dr. Neil Buddy Shah, Chief Executive Officer of CHAI. “But this goal cannot be met by Quick Start alone, and we welcome additional partners to join our consortium’s efforts.”

“In addition to identifying the most effective pathways for new product introduction and implementation of test-and-treat, our consortium will establish a learning network – open to all – across countries and sites,” said Gary Edson, President of COVID Collaborative. “By developing and sharing learnings in near-real time, we hope to catalyze and inform additional country programs and population-level scale-up.”

“Over the past two and a half years, we have seen the COVID-19 pandemic impact the health of hundreds of millions of people and claim more than six million lives,” said Christine Squires, President and CEO of Americares, one of the world’s leading nonprofit providers of donated medicine and medical supplies. “By expanding access to testing and treatment in low- and middle-income countries, we will be taking a more equitable approach to reduce hospitalizations and severe disease and, ultimately, save lives.”

“COVID-19 has exposed the massive inequities in our global health system of who can access vaccines, tests, and treatments,” said Mark Malloch-Brown, President of the Open Society Foundations. “The Open Society Foundations is proud to support the first pilot program to address the urgent gap in both testing and treating COVID-19, and which aims to demonstrate that enhancing timely access to diagnostics and low-cost antivirals can be a viable long-term solution to help end this pandemic.”
Over the past two and a half years, the COVID-19 pandemic has revealed significant global disparities in the availability of therapeutics, vaccines, testing, and other medical interventions that could limit the range and impact of the disease. In contrast, approximately hundreds of millions of HIV and malaria rapid tests are performed annually, largely in low- and middle-income countries, with treatment provided soon thereafter, highlighting the feasibility of test-and-treat approaches.

Access to treatment has become another urgent need to tackle alongside persistently low primary vaccination and booster rates in many countries. New antiviral medicines, such as PAXLOVID™ and molnupiravir, have been available in high-income countries since late 2021 but are not yet widely available in low- and middle-income countries, where self-testing must be scaled in parallel.

“The pandemic has proven that supply is only one step towards enabling greater access of COVID-19 treatments and bringing an end to the pandemic for everyone everywhere,” said Caroline Roan, Senior Vice President, Global Health & Social Impact, and Chief Sustainability Officer for Pfizer. “Broad and sustainable systems for rapid testing and diagnosis must be in place to help ensure that treatment courses can reach high-risk patients in need. We are committed to working with the global health community to address barriers to access and are proud to provide our oral treatment and financial support to further the objectives of the consortium.”

“We are proud to join our partners in the COVID Treatment Quick Start Consortium to improve access to life-saving treatments in Africa,” said Peter Laugharn, President & CEO of the Conrad N. Hilton Foundation. “The Quick Start program will center the experiences of local communities to help save lives immediately. Looking ahead, this program will lay the groundwork for equitable access to COVID testing and treatment continent-wide.”

The next step for the COVID Treatment Quick Start Consortium will be to work with Ministries of Health to begin introducing PAXLOVID™ into countries. The consortium will combine this introduction with operational research to inform how best to deploy and scale up COVID-19 test-and-treat programs in low- and middle-income countries. The initial product introduction and research will pave the way for quality assured, low-cost generic equivalent drugs, which will be critical to the sustainability of programs in partner countries.

### About the COVID Treatment Quick Start Consortium

The COVID Treatment Quick Start Consortium brings together Duke University, the Clinton Health Access Initiative (CHAI), COVID Collaborative, and Americares as implementing partners, with support from the Open Society Foundations, Pfizer and the Conrad N. Hilton Foundation. The consortium will work with national governments, multilateral agencies, and bilateral donors with a goal of supporting COVID-19 test-and-treat demonstration programs in 10 low- and middle-income countries.

### About Americares

Americares is a health-focused relief and development organization that saves lives and improves health for people affected by poverty or disaster. Each year, Americares reaches 85 countries on average, including the United States, with life-changing health programs, medicine, medical supplies and emergency aid. Americares is one of the world’s leading nonprofit providers of donated medicine and medical supplies. For more information, visit www.americares.org.
About the Clinton Health Access Initiative (CHAI)
The Clinton Health Access Initiative, Inc. (CHAI) is a global health organization committed to saving lives and reducing the burden of disease in low- and middle-income countries. We work with our partners to strengthen the capabilities of governments and the private sector to create and sustain high-quality health systems that can succeed without our assistance. For more information, visit www.clintonhealthaccess.org.

About the COVID Collaborative
The COVID Collaborative is a national bipartisan assembly of experts, leaders and institutions in health, education and the economy, and associations representing the diversity of the country, united to turn the tide on the pandemic by supporting global, federal, state, and local COVID-19 response efforts. COVID Collaborative includes former FDA commissioners, CDC directors, and U.S. surgeon generals; former U.S. secretaries of Education, Defense, Homeland Security, and Health and Human Services; leading public health experts and institutions that span the country; leading business groups and CEOs; major global philanthropies; and associations representing those on the frontlines of public health and education. For more information, visit: www.covidcollaborative.us.

About Duke University
Younger than most other prestigious U.S. research universities, Duke University consistently ranks among the very best. Its graduate and professional schools—in business, divinity, engineering, the environment, law, medicine, nursing and public policy—are among the leaders in their fields.

Duke enrolls more than 16,000 students in its undergraduate, graduate, and professional programs, and its world-class faculty is helping to expand the frontiers of knowledge. The university has a strong commitment to applying knowledge in service to society, both near its North Carolina campus and around the world. Situated on nearly 9,000 acres in Durham, North Carolina, Duke is one of the very few schools in the country, or the world, that combines academic and athletic accomplishment at the highest levels. The university is represented in the Quick Start Consortium by its Global Health Innovation Center and the Duke-Margolis Center for Health Policy.

About the Open Society Foundations
The Open Society Foundations work to build vibrant and inclusive democracies whose governments are accountable and open to the participation of all people. We are active in more than 120 countries, making us the world’s largest private funder of independent groups working for justice, democratic governance, and human rights. In 2020 and 2021, the Soros Economic Development Fund (SEDF) invested upwards of $20 million in the private sector to aid the manufacturing of vaccines, development of diagnostics, and access to medical oxygen in low- and middle-income countries. In 2022, Open Society also provided a $100 million guarantee to aid the flexible procurement of COVID-19 vaccines through COVAX’s Cost-Sharing Mechanism. For more information, visit: www.opensocietyfoundations.org.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be
important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

About the Conrad N. Hilton Foundation
International hotelier Conrad N. Hilton established the grantmaking foundation that bears his name in 1944 to help people living in poverty and experiencing disadvantage worldwide. Today, the work continues, concentrating on efforts to ensure healthy early childhood development and sustainable livelihoods for youth, support young people transitioning out of foster care, improve access to housing and support services for people experiencing homelessness, identify solutions to safe water access, and lift the work of Catholic sisters. Additionally, following selection by an independent, international jury, the Foundation annually awards the $2.5 million Conrad N. Hilton Humanitarian Prize to an organization doing extraordinary work to reduce human suffering. The Foundation is one of the world’s largest, with approximately $8.5 billion in assets. It has awarded grants to date totaling more than $2.4 billion, $339 million worldwide in 2021. For more information, visit www.hiltonfoundation.org.